Blomia tropicalis is the major asthma allergen in the tropics comparable to Dermatophagoides pteronyssinus. However, little is known about the B. tropicalis epitopes recognized by T cells. Our aim was to identify the T-cell epitopes in the major B. tropicalis allergen, Blo t 5, and investigate the potential of the corresponding peptides to inhibit the allergic inflammatory lung response. C57BL/6 mice were immunized with plasmid DNA encoding Blo t 5 and T-cell epitopes identified using the interferon-c ELI-SPOT assay with 15-mer overlapping peptides. C57BL/6 mice were sensitized with bone-marrow-derived dendritic cells (BMDC) pulsed with Blo t 5 allergen followed by intranasal Blo t 5 challenge. Two H-2 b restricted epitopes (Bt5 76-90 and Bt5 106-115 ) were recognized by CD4 T cells specific for Blo t 5, but no CD8 epitopes were identified. In mice sensitized with Blo t 5-pulsed BMDC and challenged with intranasal Blo t 5 Bt5 76-90 and Bt5 106-115 , peptide-specific CD4 T cells were found to secrete the T helper type 2 cytokines interleukin-5 and interleukin-13. Intradermal administration of synthetic peptides encoding the identified T-cell epitopes suppressed allergic airway inflammation to further allergen challenges. Hence, we have identified novel CD4 T-cell epitopes specific for Blo t 5 and demonstrated that these peptides could be employed therapeutically to suppress the T-cell response in a murine model of allergic airway inflammation.
Introduction
Mite allergens play an important role in allergic asthma. Dermatophagoides mites (particularly the house dust mite, Dermatophagoides pteronyssinus) are well studied. However, in the tropics, sensitization to allergens from the storage mite Blomia tropicalis is at frequencies comparable to Dermatophagoides pteronyssinus.
1,2 Allergens from B. tropicalis have only low to moderate cross-reactivity with antibodies against D. pteronyssinus.
3-6 Group 1 and 2 (Der p 1 and Der p 2) comprise the major house dust mite allergens that appear to interact directly with immune cells as well as lung epithelium and play a major role in allergic sensitization to house dust mite allergens [reviewed in refs 7-9] . However, these allergens only play a minor role in the allergic responses to B. tropicalis. Instead, IgE responses against this mite appear to be dominated by Blo t 5 and its paralogue Blo t 21. 6, [10] [11] [12] [13] [14] These observations suggest that B. tropicalis and D. pteronyssinus mites represent very different allergens that should be considered separately. Unfortunately, our understanding of the role played by B. tropicalis allergens in asthma pathogenesis is limited.
T helper type 2 (Th2) cells are central to the allergic airway response, secreting a number of critical cytokines, including interleukin-4 (IL-4), IL-5 and IL-13 that mediate key effects on B-cell class switching, eosinophil differentiation and recruitment and direct effects on the airways. [15] [16] [17] [18] [19] CD4 T cells recognize peptide epitopes presented in the peptide-binding groove of the class II MHC molecules present on antigen-presenting cells. Hypoallergenic proteins are currently being explored as a possible therapeutic approach for the treatment of allergic asthma. In most cases, the hypoallergenic proteins retained the epitopes recognized by T cells but were modified to omit the IgE binding regions. [20] [21] [22] In other approaches, 
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allergen-specific T-cell epitopes were also replaced so as to avoid T-cell-mediated effects. 23 Peptide immunotherapy, administration of synthetic peptides containing known allergen T-cell epitopes that inhibit T cells, has been demonstrated in animal and clinical studies. [24] [25] [26] [27] [28] Most studies on mite allergens have focused on D. pteronyssinus and T-cell epitopes identified for Der p 1 and Der p 2 proteins [29] [30] [31] [32] [33] [34] with the aim of targeting these T cells for therapy. [35] [36] [37] [38] [39] [40] However, epitopes recognized by B. tropicalis-specific T cells remain unknown and current understanding of the role of T cells in response to B. tropicalis allergens is unstudied.
The aim of our study was to identify the epitopes recognized by T cells responding to the major B. tropicalis allergen, Blo t 5. Mice were immunized using a DNA immunization strategy and the T-cell response was screened using the ELISPOT assay. Allergen-specific T cells were recruited to the lung following intranasal Blo t 5 exposure and produced Th2 cytokines such as IL-5 and IL-13. Administration of Blo t 5 peptides were tested in a murine Blo t 5-induced allergic asthma model and resulted in the suppression of the allergic inflammatory responses. We observed reduced cytokine production by allergen-specific T cells as well as a reduction in eosinophilic infiltration into the lung following allergen exposure. These data show that human paralogues of murine Blo t 5 peptides have the potential to treat asthma.
Materials and methods

Animals
Age-and sex-matched C57BL/6 and BALB/c mice (8-10 weeks old) were purchased from the animal breeding centre of the National University of Singapore. Mice were maintained under specific pathogen-free conditions. All experiments were conducted in accordance with the guidelines approved by the Institutional Animal Care and Use Committee under the protocol number 029/09.
DNA immunization constructs
Gene sequences encoding the allergen protein Blo t 5 (GenBank accession number U59102) and Der p 2 (GenBank AF276329) were codon-optimized for murine expression and synthesized by GenScript, Biomed Diagnostics Pte, Singapore. We also produced another plasmid with the Blo t 5 gene and an ovalbumin(257-264) (OVA 257-264 ) epitope cloned in-frame at the C-terminus. A Kozak initiation sequence was inserted upstream of the N-terminus of the protein. Restriction sites were inserted to facilitate downstream cloning processes. The gene sequence encoding each allergen protein was cloned into multiple cloning sites of the pVAX-1 plasmid (Thermofisher, Life Technologies Holdings, Singapore Pte). These constructs are named pVAXBlo t 5, pVAX-Der p 2 and pVAX-Blo t 5-SIINFEKL, respectively.
Immunization of mice
Mice were anaesthetized by intraperitoneal injection with a cocktail containing ketamine (7Á5% v/v) and medetomidine (10% v/v). The left leg of each anaesthetized mouse was shaved and 10 lg of plasmid DNA encoding the allergen was applied to the skin and the skin was tattooed with an 11RL needle at 100 Hz for 20 seconds as described previously. 41 
Peptides
Peptides used in this study were synthesized and isolated to >75-85% purity by GenScript.
Interferon-c ELISPOT assay
ELISPOT assays were performed using BD Mouse IFNc ESLIPOT Pair (BD Biosciences, Singapore) and Millipore Multiscreen HTS plates (Merck Pte, Singapore) in accordance with the manufacturer's instructions. The assay was developed using streptavidin-alkaline phosphatase and BCIP/NBT substrate (Mabtech, iDNA Biotechnology Pte Ltd, Singapore). Spleen and draining lymph nodes of mice were harvested and homogenized into a single-cell suspension. Red blood cell lysis was performed and cells were re-suspended in complete RPMI-1640 (Life Technologies, Sigma-Aldrich, Singapore) supplemented with 10% v/v fetal bovine serum (FBS), 1% non-essential amino acids, 1 mM sodium pyruvate, 100 IU/ml penicillin and 0Á1 mg/ml streptomycin as well as 50 lM b-mercaptoethanol. Then, 2 9 10 5 cells (cRPMI) were loaded into each well and 1 lM of the test peptides was added. Each condition was tested in triplicate. Positive control wells were supplemented with 10 ng/ml PMA and 400 ng/ml ionomycin. Background control wells contained cells, medium and peptide diluent (DMSO). The plates were incubated for 18 hr at 37°with 5% CO 2 . The plates were developed and then spots were enumerated using the CTL-Immunospot Analyzer (Cellular Technologies Limited, Biomed Diagnostics, Singapore).
Magnetic depletion of cells
CD4 or CD8 T cells were depleted using MACS magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's protocols. PBS with 2 mM EDTA and 2% FBS (MACS) buffer were used throughout and the cells were finally re-suspended in cRPMI before use.
Expression and purification of recombinant Blo t 5
Escherichia coli BL21 cells transformed with pET28 plasmid encoding Blo t 5 were grown to log-phase and protein expression was induced by the addition of 1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG). The bacterial pellet was collected and lysed by a combination of lysozyme and DNase followed by sonication. The bacterial lysate containing the Blo t 5 protein was initially enriched for the Blo t 5-containing fractions at 50% and 60% saturated ammonium sulphate precipitation. The Blo t 5 protein was subsequently purified by anion-exchange followed by size-exclusion chromatography using a GE Healthcare Life Sciences € Akta FPLC system with MonoQ 5/50 GL and HiLoad 16/60 Superdex75 columns (GE Healthcare Pte, Singapore).
Culture and antigen pulsed bone-marrow-derived dendritic cells
Bone marrow cells were isolated from the femur and cultured with 20 ng/ml granulocyte-macrophage colony-stimulating factor for 6 days with media changes every 2 days. The non-adherent cells were collected and washed before being cultured in a fresh six-well plate at a density of 4 9 10 6 cells/well. 10 lg of recombinant Blo t 5 was added to each well and the cells were cultured for 18-20 hr. The antigen-pulsed bone-marrow-derived dendritic cells (BMDC) were washed and re-suspended in Hanks' balanced salt solution before inoculation into mice.
Allergen sensitization and challenge of mice
For initial sensitization, mice were anaesthetized by intraperitoneal injection with a cocktail containing ketamine (7Á5% v/v) and medetomidine (10% v/v). Then, 1 9 10 6 antigen-pulsed BMDC were introduced intranasally into each mouse. For subsequent allergen challenges, mice were anaesthetized with 2Á5% isoflurane and challenged with 10 lg of recombinant Blo t 5.
Bronchoalveolar lavage analysis
Mice were killed, the trachea was intubated and the lungs were lavaged by two consecutive washes with 0Á5 ml of MACS buffer each. Red blood cell lysis was performed and the bronchoalveolar lavage (BAL) cells were stained and analysed by flow cytometry.
Isolation of lung and draining lymph node cells
Lungs from euthanized mice were homogenized in RPMI-1640 with 1% fetal bovine serum and digested with Liberase Blendzyme (Roche Pte, Singapore) for 45 min before mechanical disruption through a 70-micron cell strainer to obtain a single-cell suspension. For draining lymph nodes, mechanical disruption was immediately carried out without enzyme digestion. Red blood cell lysis using lysis buffer was performed and the cells were resuspended in cRPMI.
Culture of draining lymph node or lung
Cells from the lung or draining lymph nodes were cultured at density of 2 9 10 6 cells per well in cRPMI supplemented with 10 lg recombinant Blo t 5 or 10 lM of peptide. Control cells were cultured in cRPMI only. The cells were cultured at 37°and 5% CO 2 for 3-5 days and harvested for analysis.
Homogenization of lungs for cytokine analysis
The weight of the lungs was measured before homogenization. Lungs were homogenized by mechanical disruption using the Miltenyi gentleMACS (Miltenyi) dissociator without previous enzymatic digestion. Cells and cell debris were pelleted by centrifugation and the homogenate was filtered through a 41-µm membrane before storage at 80°.
Measurement of cytokines and total IgE
Cytokine levels were measured using the Mouse Duoset ELISA kits (R&D Systems, Singlab Technologies Pte, Singapore) in accordance with the manufacturer's instructions. Total IgE was measured with the OptEIA mouse IgE ELISA kit (BD Biosciences).
Flow cytometry
The following antibodies were used for staining cells: CD11c Peridinin chlorophyll protein (PerCP) -Cy5.5 (N418; eBioscience, Thermofisher Pte, Singapore), Ly-6G allophycocyanin (APC) (1A8; BioLegend, Genomax Technologies Pte, Singapore), SiglecF phycoerythrin (PE) (E50-2440; BD Pharmingen, Biomed Diagnostics Pte), CD3e eFluor450 (17A2; eBioscience) or PerCP-Cy5. To perform intracellular staining of lung-draining lymph node cells after re-stimulation, cells were further stimulated with PMA and ionomycin (Sigma-Aldrich) in the presence of Golgiplug (BD Pharmingen) and Golgistop (BD Pharmingen) for 6 hr. Cells were stained for surface markers before addition of fixation/permeabilization buffer (eBioscience) and thereafter were stained using the appropriate antibodies. Flow cytometric analysis was performed using CyAn ADP (Beckman Coulter Pte, Singapore), BD Fortessa, or BD Fortessa X-20 (BD Pharmingen) and the data were analysed using FLOWJO software (Tree Star, OR).
Statistics
Statistical analyses were performed using GRAPHPAD PRISM (La Jolla, CA, USA). Paired comparisons were performed using the Mann-Whitney U-test. Data are expressed as means AE standard errors of the means (SEM) (P values of < 0Á05, < 0Á01 and < 0Á001 are indicated as *, ** or ***). Unless specified, bar charts are shown as the mean value and error bars indicate the standard error of mean. Flow cytometric profiles and histograms are representative of repeated experiments.
Results
Optimization of DNA vaccine immunization
To validate the use of the DNA immunization approach for epitope mapping, we first assessed T-cell responses in mice immunized with a construct encoding the house dust mite allergen Der p 2. Der p 2 is a relatively wellstudied allergen compared with Blo t 5. Table 1 . The T-cell epitopes identified closely matched those previously described. 29 Interferon-c release was abrogated following the depletion of CD4 T cells through negative selection using magnetic beads [see Supplementary material, 
Identification of Blo t 5 T-cell epitopes
C57BL/6 mice were primed with pVAX-Blo t 5 and splenocytes were screened using the IFN-c ELISPOT with 15-mer peptides that overlapped with adjacent peptides by 10 amino acids spanning the entire Blo t 5-gene sequence. T-cell responses were observed for 15-mers #16, #21 and #22 (Fig. 1a) . To determine if the responding T cells were CD4 or CD8, we depleted CD4-or CD8-positive cells using anti-CD4 or anti-CD8 magnetic beads before the ELISPOT assay. Depletion of CD4 cells completely abrogated detection of any peptide-specific IFN-c + cells whereas depletion of CD8 cells failed to do so, indicating that the Blo t 5 peptides were recognized by CD4 and not CD8 T cells (Fig. 1b) . Next, we used incrementally truncated peptides to identify the minimal epitopes recognized by CD4 T cells from C57BL/6 mice (Fig. 1c,d ). The peptides were truncated from both the N-terminus and C-terminus and cultured with cells from pVAX-Blo t 5 immunized mice and T-cell responses to the peptides were measured using the IFN-c ELISPOT. For peptides #21 and #22, we hypothesized that the minimal epitope lay within the region of overlap between the peptides and this did indeed prove to be the case. We identified the minimal epitopes as LDVVCAMIEGAQG (within peptide #16) and NYEEAQTLSK (between peptide #21 and #22), respectively. We also examined the response to pVAX-Blo t 5 in BALB/c mice ( Fig. 1e) and identified two epitopes, 15 and 16 that again were CD4 epitopes (Fig. 1f) .
Respiratory response of Blo t 5 DNA vaccinated mice to recombinant Blo t 5 protein
To verify that Blo t 5-specific CD4 T cells identified in our study can be induced in the lung immune response to Blo t 5, we primed mice with pVAX-Blo t 5 and subsequently challenged them intranasally with recombinant Blo t 5 as shown in the schema (Fig. 2a) . Control mice were primed with the native pVAX1 plasmid and subsequently challenged with Blo t 5 protein in the same manner. BAL eosinophilia was observed in the mice that had been primed with pVAX-Blo t 5 before intranasal allergen exposure (Fig. 2b) . This was not observed in control mice. Culture of cells from the draining lymph nodes of these mice with either recombinant Blo t 5 or antigenic peptides identified in the earlier screening predominantly produced the Th2 cytokines IL-5 and IL-13 and a smaller amount of IL-10 or very little IFN-c and no IL-4 (Fig. 2c) . Comparable amounts of these cytokines were induced by culture with either Blo t 5 and or peptide 16 but much less with peptides 21 and 22 (Fig. 2c) . Intracellular cytokine staining of ex vivo stimulated CD4 T cells identified 5Á5% IL-5-positive and 3Á3% IL-13-positive CD4 T cells from the lymph nodes of pVAX-Blo t 5 of an individual primed mouse (Fig. 2d) . Again peptide 16 generated as many of these cells as whole Blo t 5 (Fig. 2d) . The collated data from the groups of mice are shown in Figure 2 (e).
Respiratory response of Blo t 5-pulsed BMDC inoculated mice to recombinant Blo t 5 protein
We established an alternative Blo t 5 sensitization and challenge model as we found that the skin tattoo method was rather variable. Mice were sensitized to Blo t 5 by the intranasal administration of 1 9 10 6
Blo t 5-pulsed BMDC followed by intranasal Blo t 5-challenge on Days 14, 16 and 18 (Fig. 3a) . Mice were culled on Day 21. Marked eosinophilia were observed from mice sensitized and challenged using this protocol (Fig. 3b) . Draining lymph node cells cultured with Blo t 5 or peptides #16, #21 and #22 secreted IL-5 and IL-13, determined using both intracellular cytokine staining (Fig. 3c) and ELISA (Fig. 3d) . This demonstrated that the T cells recognizing the epitopes identified following plasmid DNA immunization were indeed generated following exposure to Blo t 5 and contribute to Th2 lung inflammation and that T cells responding to peptide #16 dominate the airway response to Blo t 5.
Treatment of mice with allergen peptide inhibited the inflammatory airway response to Blo t 5 challenge
Peptide immunotherapy using synthetic peptides encoding known T-cell epitopes has been demonstrated to be effective in suppressing the allergic immune responses to allergens Fel d 1 and Der p 1 in mice. 26, 27 We determined whether synthetic peptides encoding the epitopes identified in this study could function in a similar manner. Mice were sensitized by the intranasal instillation of 1 9 10 6 BMDC pulsed with Blo t 5 followed by intranasal challenges with Blo t 5. Mice were then inoculated intradermally with a mixture of synthetic peptides containing the T-cell epitopes before a second series of intranasal Blo t 5 challenges (Fig. 4a ). Mice were culled 3 days following the last allergen challenge and BAL was analysed for immune cell infiltration. In mice that had received the Blo t 5 peptides, there was a marked reduction in BAL (Fig. 4b) and lung (Fig. 4c) eosinophilia compared with mice given the control peptide (OVA 323-339 ). However, in Blo t 5 peptide-treated mice, production of the Th2 cytokines IL-5 and IL-13 was not significantly decreased in cultures of BAL cells (Fig. 4d) , but IL-13 was reduced in the cultures of lung cells (Fig. 4e) and both IL-5 and IL-13 were reduced in cultures of mesenteric lymph node cells (Fig. 4f) each cultured with Blo t 5. We did not observe a significant effect of peptide treatment on serum IgE (Fig. 4g) .
Mechanism of peptide inhibition of the allergic lung response
To investigate the mechanism of peptide inhibition of eosinophilia and Th2 cytokines we determined the number of CD3 + CD4 + FoxP3 + regulatory T cells in peptide-treated mice. We did not find any difference in the number of FoxP3 + cells (Fig. 5a ) or the intensity of the FoxP3 staining (Fig. 5b) . Nor did we observe any difference in IL-10 production in lymph node cultures (Fig. 5c ) or in the lung homogenate (Fig. 5d ) or in the Th1 cytokine IFN-c (Fig. 5e) .
Peptide therapy reduced the number of Th2 cells
The percentage of IL-5-producing lung T cells was reduced in mice that had received the Blo t 5 peptides before allergen challenge compared with the mice that received control peptides (Fig. 6a) . However, the proportion of cells producing IL-13 was not significantly affected. We observed a reduction in the number of T1/ ST2 expressing CD4 T cells, generally recognized as the population of Th2-polarized T cells (Fig. 6b) . This suggested that the strength of the Th2 T-cell response against the allergen was reduced in the peptide-treated mice. We also assessed the expression level of PD-1 on the lunginfiltrating T cells and observed a small but significant increase in PD-1 expression in T cells from mice that had received the Blo t 5 peptide compared with the mice that received the control peptides (Fig. 6c) .
Discussion
T cells play a critical role in the pathogenesis of asthma. In this study, we identified two epitopes recognized by Blo t 5-specific CD4 T cells using DNA immunization. This approach was chosen because it allows for rapid screening of various allergen epitopes. This approach was validated using Der p 2 as a model allergen. Der p 2 is a relatively well-studied allergen protein compared with Blo t 5 and T-cell epitopes recognized by mouse T cells were previously described. 29, 33 We identified Der p 2 epitopes that generally agreed with those described in Hoyne et al. 29 We also demonstrated that immunization using this approach can induce a strong CD8 T-cell response through the inclusion of a known class I MHC epitope within the immunization construct. This showed that DNA immunization resulted in the expression of the allergen protein (with the included SIINFEKL epitope) that was subsequently processed through the MHC class I as well as the MHC class II pathway. We further demonstrated that T cells recognizing Blo t 5 epitopes identified in this study were recruited to the lungs following allergen exposure and induced asthma-like allergic airway inflammation characterized by BAL and lung eosinophilia and production of Th2 cytokines. We also showed that these T cells could be targeted using peptide immunotherapy to reduce the allergic airway inflammatory response to the Blo t 5.
Interleukin-10 and regulatory T cells have been reported to suppress Th2 allergic inflammation following allergen-specific immunotherapy in several studies, including peptide immunotherapy. 26, 27, 38, 39, 42, 43 An increase in FoxP3-positive cells following peptide immunotherapy has been described 26, 27 whereas increased FoxP3 expression by T cells has also been observed. 26 However, we were unable to see a change in regulatory T-cell numbers or IL-10 production following peptide treatment. We did observe a decline in the Blo t 5-specific T-cell response compared with control and the number of T cells expressing the Th2 marker T1/ST2 was significantly lower in the lung of mice that had received peptide immunotherapy before antigen challenge compared with the control mice. Furthermore, T cells producing the Th2 cytokine IL-5 were significantly reduced in the peptide immunotherapy group.
Another suggested mechanism in the suppression of the T-cell function by peptides was through the induction of T-cell anergy or deletion. 44, 45 This suggests that a portion of the allergic T-cell population may have been rendered anergic or even deleted following peptide treatment. PD-1 has been demonstrated to have an inhibitory effect on T-cell function and is expressed at higher levels on exhausted T cells. 46, 47 We examined the levels of PD-1 on T cells from these mice, following peptide administration. We found that PD-1 expression was slightly increased in the treated mice. PD-1 is recognized as a marker for T-cell exhaustion and the interaction between PD-1 and its ligand PDL-2 appears to negatively regulate allergic inflammation and airway hyperresponsiveness (reviewed in ref. 48) . We believe that this indicates that peptide administration may have induced a state of anergy (unresponsiveness) in allergen-specific T cells and reduced their response to subsequent allergen exposure. To confirm this in vivo neutralization of PD-1 and PD-L1/L2 would have helped answer this question. Induction of a Th1 response has also been proposed as a possible mechanism to counter a Th2 response;
49,50 however, we did not see any change in IFN-c, indicating that our approach did not induce a Th1 response.
We have identified for the first time the CD4 Tcell-restricted peptide of Blo t 5 using a novel approach to allergen immunization. We have shown that airway sensitization to Blo t 5 induces T cells that recognize these peptides and that administration of peptides after sensitization attenuated the ongoing inflammatory response. 
